Global Information
회사소개 | 문의 | 위시리스트

세계의 백신 수탁 제조 시장 예측(2019-2029년)

Global Vaccine Contract Manufacturing Market Report 2019-2029

리서치사 Visiongain Ltd
발행일 2019년 04월 상품 코드 347364
페이지 정보 영문 217 Pages
가격
£ 3,499 ₩ 5,286,000 Unprintable PDF (Single User) - 1 Year License help
1명만 이용할 수 있는 라이센스입니다. DRM(디지털 저작권 관리 시스템) 장착 PDF 파일로, 인증된 PC 1대에서만 열람이 가능하며, 구입일로부터 1년간 유효합니다. PDF 파일은 Copy & Paste 가 되지 않으며, 인쇄 또한 불가능합니다.
£ 3,899 ₩ 5,891,000 PDF (Departmental - 5 Users) - 1 Year License help
동일 사업장(소재지) 내 5명까지 이용할 수 있는 라이센스입니다. DRM(디지털 저작권 관리 시스템) 장착 PDF 파일로, 인증된 PC에서만 열람이 가능하며, 구입일로부터 1년간 유효합니다. PDF파일은 Copy & Paste가 되지 않으며, 인쇄는 1명당 1회에 한해 가능합니다. 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
£ 4,999 ₩ 7,553,000 PDF (Site License) help
동일 사업장(소재지) 내 모든 분이 이용할 수 있는 라이센스입니다. 이용 인원수 제한은 없습니다. PDF 파일은 Copy & Paste 가 되지 않습니다. DRM(디지털 저작권 관리시스템)은 적용되어 있지 않지만, PDF 인쇄는 1명당 1회에 한해 가능합니다. 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
£ 6,999 ₩ 10,575,000 PDF (Global Site License - Includes Free Datasets) help
동일 기업의 전세계 분들이 이용할 수 있는 라이센스입니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste 가 되지 않습니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



세계의 백신 수탁 제조 시장 예측(2019-2029년) Global Vaccine Contract Manufacturing Market Report 2019-2029
발행일 : 2019년 04월 페이지 정보 : 영문 217 Pages

세계의 백신 수탁 제조(Vaccine Contract Manufacturing) 시장에 대해 조사 분석했으며, 매출과 성장 예측, 시장 점유율, 주요 국가, 주요 기업, 동향과 SWOT 분석 등에 대한 체계적인 정보를 제공합니다.

제1장 보고서 개요

제2장 백신 소개

  • 백신의 역사
  • 백신의 구조
    • 인공 면역
  • 백신의 종류
    • 약독화 생백신(LAV)
    • 재조합 생백신
    • 불활화 백신
    • 톡소이드 백신
    • 아단위 백신
    • 접합 백신
    • 재조합 아단위 백신
    • DNA 백신
    • 재조합 벡터 백신
    • 치료 백신
  • 백신으로 예방할 수 있는 질환
  • 백신 시장의 성장
  • 기술 및 규제의 개선

제3장 백신 제조 기술

  • 백신 기술 동향 요약
  • 백신 제조의 신기질
  • 차세대 발현 시스템과 벡터
  • 기구 동향
  • 프리필드 시린지와 백신
  • 동결건조와 백신 제조
  • 세포 배지

제4장 세계의 백신 제조 시장

  • 세계의 백신 제조 시장 개요
  • 세계의 백신 시장 예측
  • 세계의 백신 시장 : 2차 시장별
  • 백신 시장의 성장이 백신 제조 효율을 촉진
  • 소아용 백신 시장 개요
  • 성인용 예방 백신 시장 개요
  • 인플루엔자 백신 시장 개요
  • 치료 백신 시장 개요

제5장 세계의 백신 수탁 제조

  • 의약품 및 바이오테크놀러지 산업의 아웃소싱
  • 의약품 수탁 제조 기관(CMO)
  • 의약품 수탁 제조 시장 : 총매출 예측
  • 백신 수탁 제조 시장

제6장 백신 수탁 제조 시장 : 백신 종류별

  • 소아용 백신
  • 성인용 백신
  • 인플루엔자 백신
  • 치료 백신

제7장 백신 수탁 제조 시장 : 워크플로우별

  • 다운스트림 공정
  • 업스트림 공정

제8장 주요 국가의 백신 수탁 제조 시장

  • 주요 국가의 백신 수탁 제조 시장
  • 북미
  • 유럽
  • 아시아태평양
  • 기타 지역

제9장 백신 수탁 제조의 주요 기업

  • 백신 수탁 제조의 주요 기업
  • Baxter BioPharma Solutions
  • Boehringer Ingelheim
  • Catalent
  • Charles River Laboratories
  • IDT Biologika GmbH
  • Lonza
  • Meridian Life Science
  • Sigma-Aldrich Fine Chemicals(SAFC)(Merck KGaA)
  • SynCo Bio Partners
  • AbbVie Contract Manufacturing
  • Evonik Degussa
  • Vetter Pharmaceutical
  • Pfizer CentreOne
  • Nipro Corporation

제10장 세계의 백신 제조 시장 : 세계 시장 동향

  • 백신 수탁 제조업의 동향
  • SWOT 분석

제11장 결론

부록

KSM 19.06.17

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Table 2.1: Timeline of Key Events in Vaccine Development, c.1000 AD - Present
  • Table 3.1: Vaccine Development Pipeline Using Crucell's AdVac Technology
  • Table 3.2: Benefits and Drawbacks of Using Disposable Technology for Vaccine Production
  • Table 3.3: Companies Providing Disposable Biomanufacturing Platforms/Systems
  • Table 3.4: Some Leading Pre-Filled Syringe Vaccine Products
  • Table 3.5: Prominent Lyophilised Vaccines
  • Table 3.6: Examples of Serum-Free Media for Vaccine Manufacturing
  • Table 4.1: The Global Vaccine Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) 2018-2029
  • Table 4.2: The Global Vaccine Market: Revenue ($bn) and Market Share by Submarket (%), 2018-2019
  • Table 5.1: The Global Vaccine Contract Manufacturing Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 6.1: Global Paediatric Vaccines Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 6.2: Global Adult Vaccines Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 6.3: Global Influenza Vaccines Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 6.4: Global Therapeutic Vaccines Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 7.1: Global Downstream Processing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 7.2: Global Fill & Finish Operations Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 7.3: Global Analytical & QC Studies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 7.4: Global Packaging Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 7.5: Global Upstream Processing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 7.6: Global Mammalian Expression Systems Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 7.7: Global Bacterial Expression Systems Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 7.8: Global Yeast Expression Systems Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 7.9: Global Baculovirus/Insect Expression Systems Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 7.10: Global Other Upstream Processing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.1: Leading National Vaccine Contract Manufacturing Markets Forecast: Revenue ($m) and Market Share (%), 2018-2019
  • Table 8.2: North America Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.3: North America Vaccine Contract Manufacturing Market, By Vaccine Type Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.4: North America Vaccine Contract Manufacturing Market by Workflow Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.5: North America Downstream Processing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.6: North America Upstream Processing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.7: US Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.8: Canada Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.9: Europe Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.10: Europe Vaccine Contract Manufacturing Market by Vaccine Type Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.11: Europe Vaccine Contract Manufacturing Market by Workflow Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.12: Europe Downstream Processing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.13: Europe Upstream Processing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.14: Germany Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.15: UK Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.16: France Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.17: Italy Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.18: Spain Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.19: Asia-Pacific Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.20: Asia-Pacific Vaccine Contract Manufacturing Market by Vaccine Type Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.21: Asia-Pacific Vaccine Contract Manufacturing Marke by Workflow Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.22: Asia Pacific Downstream Processing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.23: Asia Pacific Upstream Processing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.24: Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.25: Chinese Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.26: Indian Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.27: RoW Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.28: RoW Vaccine Contract Manufacturing Market by Vaccine Type Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.29: RoW Vaccine Contract Manufacturing Market by Workflow Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.30: RoW Downstream Processing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.31: RoW Upstream Processing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.32: Brazilian Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.33: Mexican Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.34: Russian Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 8.35: South Africa Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2018-2029
  • Table 9.1: Baxter BioPharma Solutions Overview
  • Table 9.2: Baxter BioPharma Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2013-2018
  • Table 9.3: Boehringer Ingelheim Biopharmaceuticals Overview
  • Table 9.4: Boehringer Ingelheim: Biopharmaceuticals Revenue ($m) and Annual Growth Rate (%), 2012-2018
  • Table 9.5: Catalent Overview
  • Table 9.6: Catalent: Revenue($m) and AGR (%), 2012-2018
  • Table 9.7: Charles River Laboratories: Revenue ($m) and AGR (%), 2012-2018
  • Table 9.8: Charles River Laboratories: Newly Revised Reportable Segments
  • Table 9.9: Charles River Laboratories: cGMP Vaccine Manufacturing and Testing Capabilities
  • Table 9.10: Lonza Custom Manufacturing: Revenue ($m) and AGR (%), 2010-2016
  • Table 9.11: Meridian Bioscience: Revenue ($m), AGR (%), 2012-2018
  • Table 9.12: SynCo Bio Partners Capabilities
  • Table 9.13: AbbVie Contract Manufacturing: Details, 2017
  • Table 9.14: Evonik Degussa Details, 2018
  • Table 9.15: Vetter Details, 2017
  • Table 9.16: Vetter Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2013-2017
  • Table 9.17: Pfizer CentreOne Details, 2018
  • Table 9.18: Pfizer CentreSource: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2013-2018
  • Table 9.19: Nipro Pharma Overview
  • Table 9.20: Nipro Pharmaceutical Contract Manufacturing Capabilities: 2011-2017
  • Table 10.1: SWOT Analysis of the Vaccine Contract Manufacturing Market

List of Figures

  • Figure 3.1: Influenza Vaccine Production Using a Cell-Based Manufacturing Method
  • Figure 3.2: Medicago's Product Pipeline
  • Figure 3.3: Novavax' Insect Egg-Based Vaccine Production Process
  • Figure 3.4: Pre-filled Syringes Market: Drivers and Restraints, 2019-2029
  • Figure 4.1: The Global Vaccine Market Forecast: Revenue ($bn), AGR (%) 2018-2029
  • Figure 4.2: The Global Vaccine Market: Market Share by Submarket (%), 2018
  • Figure 5.1: Selected Tasks Outsourced in the Pharmaceutical and Biotech Industry
  • Figure 5.2: Global Vaccine Contract Manufacturing Forecast: Revenue ($m), 2019, 2023 and 2029
  • Figure 5.3: The Global Vaccine Contract Manufacturing Forecast: Revenue ($Mn) and AGR (%), 2018-2029
  • Figure 6.1: Global Vaccine Contract Manufacturing Forecast by Vaccine Type: Revenue ($m), 2018-2029
  • Figure 6.2: Global Vaccine Contract Manufacturing Forecast by Vaccine Type: Market Share (%), 2018-2029
  • Figure 6.3: Global Paediatric Vaccines Market Forecast: Revenue ($m) and AGR (%), 2018-2029
  • Figure 6.4: Global Adult Vaccines Market Forecast: Revenue ($m) and AGR (%), 2018-2029
  • Figure 6.5: Global Influenza Vaccines Market Forecast: Revenue ($m) and AGR (%), 2018-2029
  • Figure 6.6: Global Therapeutic Vaccines Market Forecast: Revenue ($m) and AGR (%), 2018-2029
  • Figure 7.1: Global Vaccine Contract Manufacturing Forecast by Workflow: Revenue ($m), 2018-2029
  • Figure 7.2: Global Vaccine Contract Manufacturing Forecast, By Workflow: Market Share (%), 2018-2029
  • Figure 7.3: Global Downstream Processing Market Forecast: Revenue ($m) and AGR (%), 2018-2029
  • Figure 7.4: Global Fill & Finish Operations Market Forecast: Revenue ($m) and AGR (%), 2018-2029
  • Figure 7.5: Global Analytical & QC Studies Market Forecast: Revenue ($m) and AGR (%), 2018-2029
  • Figure 7.6: Global Packaging Market Forecast: Revenue ($m) and AGR (%), 2018-2029
  • Figure 7.7: Global Upstream Processing Market Forecast: Revenue ($m) and AGR (%), 2018-2029
  • Figure 7.8: Global Mammalian Expression Systems Market Forecast: Revenue ($m) and AGR (%), 2018-2029
  • Figure 7.9: Global Bacterial Expression Systems Market Forecast: Revenue ($m) and AGR (%), 2018-2029
  • Figure 7.10: Global Yeast Expression Systems Market Forecast: Revenue ($m) and AGR (%), 2018-2029
  • Figure 7.11: Global Baculovirus/Insect Expression Systems Market Forecast: Revenue ($m) and AGR (%), 2018-2029
  • Figure 7.12: Global Other Upstream Processing Market Forecast: Revenue ($m) and AGR (%), 2018-2029
  • Figure 8.1: The Leading National Vaccine Contract Manufacturing: Market Share (%) by Region, 2018
  • Figure 8.2: North America Vaccine Contract Manufacturing: Market Share (%) by Region, 2018-2029
  • Figure 8.3: U.S. Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2018-2029
  • Figure 8.4: Canada Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2018-2029
  • Figure 8.5: Europe Vaccine Contract Manufacturing: Market Share (%) by Region, 2018-2029
  • Figure 8.6: Germany Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2018-2029
  • Figure 8.7: UK Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2018-2029
  • Figure 8.8: France Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2018-2029
  • Figure 8.9: Italy Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2018-2029
  • Figure 8.10: Spain Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2018-2029
  • Figure 8.11: Asia-Pacific Vaccine Contract Manufacturing: Market Share (%) by Region, 2018-2029
  • Figure 8.12: Japanese Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2018-2029
  • Figure 8.13: Chinese Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2018-2029
  • Figure 8.14: Indian Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2018-2029
  • Figure 8.15: RoW Vaccine Contract Manufacturing: Market Share (%) by Region, 2018-2029
  • Figure 8.16: Brazilian Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2018-2029
  • Figure 8.17: Mexican Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2018-2029
  • Figure 8.18: Russia Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2018-2029
  • Figure 8.19: South Africa Vaccine Contract Manufacturing Market Forecast: Revenue ($m) and AGR (%), 2018-2029
  • Figure 9.1: Baxter BioPharma Manufacturing: Revenue ($m), 2013-2018
  • Figure 9.2: Boehringer Ingelheim: Biopharmaceuticals Revenue ($m) and Annual Growth Rate (%), 2012-2018
  • Figure 9.3: Catalent: Revenue ($m) and AGR (%), 2012-2018
  • Figure 9.4: Catalent Financial Performance by Division: Revenue ($m), 2013-2018
  • Figure 9.5: Charles River Laboratories: Revenue ($m) and AGR (%), 2012-2018
  • Figure 9.6: Lonza Custom Manufacturing: Revenue ($m) and AGR (%), 2010-2016
  • Figure 9.7: Meridian Bioscience: Revenue ($m), and AGR (%), 2012-2018
  • Figure 9.8: Nipro Pharmaceutical Contract Manufacturing Capabilities: Orally Administered Drugs, Injectables, External Preparations, 2011-2017
  • Figure 10.1: Drivers and Restraints for the Vaccine Contract Manufacturing Sector
  • Figure 11.1: The Global Vaccine Contract Manufacturing Market: Market Share by Region (%), 2018, 2023, 2029
  • Figure 11.2: The Global Vaccine Contract Manufacturing: National Market Share (%), 2018 - 2029

COMPANIES LISTED:

  • AbbVie
  • Accugenix
  • AfriVax
  • Alkion Biopharma SAS
  • AmProtein
  • Antigenics, Inc.
  • Arabio
  • Argenta
  • Artelis
  • Astrazeneca
  • ATM Life Sciences
  • ATMI
  • Bacteriological Institute of the Anhaltian Administrative Areas
  • Batavia Bioservices
  • Baxter BioPharma
  • Berna Biotech
  • Bharat Biotech International Limited
  • Binnopharm
  • BioFocus
  • Biovest
  • Boehringer Ingelheim
  • Bristol-Myers Squibb Company
  • Cadila Pharmaceuticals
  • Calico
  • Catalent
  • Cellexus Limited
  • Charles River Laboratories
  • Chemisch-Pharmazeutisches Laboratorium Ravensburg
  • Colorcon
  • Crucell
  • CSL Biotherapies
  • Daiichi Sankyo Co. Ltd.
  • Elanco
  • Eli Lilly
  • Evonik Degussa
  • FiberCell
  • Gallant Custom Laboratories
  • GE Healthcare
  • GE Wave Biotech
  • GlaxoSmithKline Biologics
  • GSAL
  • GlaxoSmithKline (GSK)
  • Hikma
  • Hyclone
  • IDT Biologika GmbH
  • Intercell Corporation
  • Invitrogen
  • Irvine Scientific
  • Janssen Biotech, Inc. (Janssen)
  • Klocke Group
  • Kuhner
  • LG Life Sciences
  • Lonza
  • Medicago
  • Meissner Filtration
  • Merck & Company
  • Merck Millipore
  • Meridian Bioscience
  • Meridian Life Science
  • MGC Pharma Co.
  • Millipore
  • Mitsubishi Tanabe Pharma
  • MorphoSys
  • Mosquirix
  • MP Biomedicals
  • Mylan
  • Neurocrine Biosciences
  • Nipro Corporation
  • Novartis
  • Novartis Vaccines and Diagnostics
  • Novavax
  • Organon Teknika Corporation
  • Pall Life Sciences
  • PATH
  • Patheon
  • Pfizer
  • Pharmaceutical Base Development Co., Ltd.
  • Pharmacyclics LLC
  • Philip Morris International
  • Pierre-Guerin Biolafitte
  • Protein Sciences Corporation
  • Refine Technology
  • Samsung Bioepis
  • Sanofi
  • Sanofi Pasteur
  • Sartorius Stedim Biotech
  • Scripps Research
  • Shanghai Zhangjiang Biotech
  • ShangPharma Corporation
  • Sigma Aldrich
  • Sigma-Aldrich Fine Chemicals
  • SynCo Bio Partners
  • SynCo Bio Partners (SynCo)
  • Thermo Fisher
  • Vetter Pharmaceutical
  • Vivalis
  • Voyager Therapeutics, Inc.
  • Wave Biotech (GE Healthcare Life Sciences)
  • Wynca
  • Xcellerex (GE Healthcare Life Sciences)
  • ZellWerk
  • Zhejiang Jiang Yuan Tang Biotechnology Corporation

List of Organizations Mentioned in the Report:

  • Centers for Disease Control and Prevention (CDC)
  • Defense Advanced Research Projects Agency (DARPA)
  • European Medicine Agency (EMA)
  • Food and Drug Administration (FDA)
  • Institute Pasteur in Paris
  • Japanese Ministry of Health, Labour and Welfare (MHLW)
  • National Institute of Allergy and Infectious Diseases (NIAID)

Title:
Global Vaccine Contract Manufacturing Market Report 2019-2029
Paediatric Vaccines, Adult Vaccines, Influenza Vaccines, Therapeutic Vaccines, Downstream Processing, Fill & Finish Operations, Analytical & QC Studies, Packaging, Upstream Processing, Mammalian Expression Systems, Bacterial Expression Systems, Yeast Expression Systems, Baculovirus/Insect Expression Systems, Other Upstream Processing.

The global vaccine contract manufacturing market was worth $1.9bn in 2018 and is expected to grow at a CAGR of 9.3% from 2019-2023. In 2018, the paediatric vaccines segment held 48% of the global vaccine contract manufacturing market.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 217-page report you will receive 80 tables and 57 figures - all unavailable elsewhere.

The 217-page report provides clear detailed insight into the global vaccine contract manufacturing market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

  • Revenue and growth forecasts from 2019 to 2029 for the global vaccine market
  • Revenue and growth forecasts from 2019 to 2029 for the global vaccine contract manufacturing market

Revenue and growth forecasts from 2019 to 2029 for the global vaccine contract manufacturing market by type:

  • Paediatric Vaccines
  • Adult Vaccines
  • Influenza Vaccines
  • Therapeutic Vaccines

Revenue and growth forecasts from 2019 to 2029 for the global vaccine contract manufacturing market by workflow:

  • Downstream Processing: the revenues are further broken down into Fill & Finish Operations, Analytical & QC Studies, Packaging
  • Upstream Processing: the revenues are further broken down into Mammalian Expression Systems, Bacterial Expression Systems, Yeast Expression Systems, Baculovirus/Insect Expression Systems, Other Upstream Processing
  • Revenue and growth forecasts from 2019 to 2029 for the leading regional and national markets:
  • North America: the revenues are further broken down into the US and Canada
  • Europe: the revenues are further broken down into the UK, Germany, France, Italy and Spain
  • Asia-Pacific: the revenues are further broken down into China, Japan and India
  • Rest of the World: the revenues are further broken down into Brazil, Mexico, Russia and South Africa

The regional markets are further broken down by type and workflow.

Discussion and profiles of the leading players in the vaccine contract manufacturing market:

  • AbbVie
  • Baxter BioPharma Solutions
  • Boehringer Ingelheim
  • Catalent
  • Charles River Laboratories
  • Evonik Degusa
  • IDT Biologika
  • Lonza
  • Meridian Life Science
  • Nipro Corporation
  • Pfizer CentreOne
  • Sigma Aldrich Fine Chemicals
  • SynCo Bio Partners
  • Vetter Pharmaceutical

A SWOT analysis discussing the industry trends, strengths, weaknesses, opportunities and threats.

Discussion on vaccine manufacturing technologies covering new substrates for vaccine production, next-generation expression systems and vectors, equipment trends, pre-filled syringes and vaccines, lyophilization and vaccine manufacturing, cell-based techniques.

Key Questions Answered by this Report:

  • How is the vaccine contract manufacturing market evolving?
  • What is driving and restraining the vaccine contract manufacturing market?
  • What are the market shares of the leading segments of the vaccine contract manufacturing market in 2018?
  • What is the value of the leading sectors in important regions of the world?
  • What will be the main driver of the overall market from 2019 to 2029?
  • How will political and regulatory factors influence the regional markets and submarkets?
  • Will leading national vaccine contract manufacturing markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the leading national markets change by 2029 and which country will lead the market in 2029?
  • How will the industry evolve during the period between 2019 and 2029?

Visiongain's study is intended for anyone requiring commercial analyses for the global vaccine contract manufacturing market. You find data, trends and predictions.

Buy our report today Global Vaccine Contract Manufacturing Market Report 2019-2029: Paediatric Vaccines, Adult Vaccines, Influenza Vaccines, Therapeutic Vaccines, Downstream Processing, Fill & Finish Operations, Analytical & QC Studies, Packaging, Upstream Processing, Mammalian Expression Systems, Bacterial Expression Systems, Yeast Expression Systems, Baculovirus/Insect Expression Systems, Other Upstream Processing.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. World Vaccine Contract Manufacturing Market Highlights
  • 1.2. Why You Should Read This Report?
  • 1.3. How This Report Delivers
  • 1.4. Key Questions Answered by This Analytical Report
  • 1.5. Who is This Report For?
  • 1.6. Methodology
  • 1.7. Associated Visiongain Reports
  • 1.8. Frequently Asked Questions (FAQ)

2. Introduction to Vaccines

  • 2.1. The History of Vaccines
  • 2.2. How Do Vaccines Work?
    • 2.2.1. Artificial Immunity
  • 2.3. Types of Vaccine
    • 2.3.1. Live, Attenuated Vaccines (LAVs)
    • 2.3.2. Recombinant Live Vaccines
    • 2.3.3. Inactivated Vaccines
    • 2.3.4. Toxoid Vaccines
    • 2.3.5. Subunit Vaccines
    • 2.3.6. Conjugate Vaccines
    • 2.3.7. Recombinant Subunit Vaccines
    • 2.3.8. DNA Vaccines
    • 2.3.9. Recombinant Vector Vaccines
    • 2.3.10. Therapeutic Vaccines
  • 2.4. Diseases Preventable with Vaccines
  • 2.5. The Rise of the Vaccines Market
  • 2.6. Technological and Regulatory Improvements

3. Vaccine Manufacturing Technologies, 2018

  • 3.1. Summary of Vaccine Technology Trends
  • 3.2. New Substrates for Vaccine Production
    • 3.2.1. Shift towards Cell-Based Manufacturing Technology
    • 3.2.2. Benefits of Cell-Based Techniques
    • 3.2.3. Mammalian Cell Lines
      • 3.2.3.1. Madin Darby Canine Kidney Cells (MDCK)
      • 3.2.3.2. Vero Cells
      • 3.2.3.3. PerC6 Cells
    • 3.2.4. Avian-Derived Cell Lines
      • 3.2.4.1. EB66 Stem Cell Technology: Vivalis
    • 3.2.5. Plant-Based Vaccines
      • 3.2.5.1. Medicago's Proficia VLP Vaccine Technology
    • 3.2.6. Insect Egg-Based Production Systems
      • 3.2.6.1. Novavax
      • 3.2.6.2. Protein Sciences Corporation (PSC)
  • 3.3. Next-Generation Expression Systems and Vectors: Increasing Production Yield
    • 3.3.1. AdVac Technology: Crucell
    • 3.3.2. AdCEV Vectors: AfriVax
    • 3.3.3. Pfenex Expression Technology: Pfenex
  • 3.4. Equipment Trends
    • 3.4.1. The Shift Towards Disposable Single-use Equipment
    • 3.4.2. Bioreactors and Vaccine Production
      • 3.4.2.1. Single-Use Bioreactors
      • 3.4.2.2. Main Applications of Disposable Bioreactors
      • 3.4.2.3. Current Single-Use Bioreactor Systems in the Market
  • 3.5. Prefilled Syringes and Vaccines
    • 3.5.1. Growing Market for Pre-Filled Syringes
    • 3.5.2. Pre-Filled Vaccine Products
    • 3.5.3. Drivers and Restraints for Pre-Filled Syringes
    • 3.5.4. Product Stability and Quality Assurance Programme
      • 3.5.4.1. Paediatric H1N1 Vaccine
      • 3.5.4.2. Reported Challenges Flu Vaccines
      • 3.5.4.3. Novartis' Agriflu and Fluad Ban is Lifted
      • 3.5.4.4. Baxter Flu Vaccine and Side Effects
      • 3.5.4.5. Reported Shelf Life with H1N1 Vaccine
  • 3.6. Lyophilisation and Vaccine Manufacturing
    • 3.6.1. Lyophilisation of Vaccines Will Increase
  • 3.7. Cell Media Can Improve Virus Yield

4. The Global Vaccine Manufacturing Market 2019-2029

  • 4.1. Overview of the Global Vaccine Manufacturing Market 2019-2029
  • 4.2. World Vaccine Market Forecast 2019-2029
  • 4.3. The Global Vaccine Market by Submarket, 2018 and 2019
  • 4.4. Growth in Vaccine Market Will Drive Efficiency in Vaccine Manufacturing
  • 4.5. Paediatric Vaccines Market Overview
  • 4.6. Adult Prophylactic Vaccines Market Overview
  • 4.7. Influenza Vaccines Market Overview
  • 4.8. Therapeutic Vaccines Market Overview

5. The Global Vaccine Contract Manufacturing 2019-2029

  • 5.1. Outsourcing in the Pharmaceutical and Biotechnology Industry
    • 5.1.1. Reasons to Outsource
    • 5.1.2. Benefits of Outsourcing
    • 5.1.3. The Challenges in Outsourcing Vaccine Manufacturing
    • 5.1.4. Why Should Companies Outsource Vaccine Manufacturing?
    • 5.1.5. Strategic Outsourcing Vs Tactical Outsourcing
    • 5.1.6. Virtual Companies
  • 5.2. Contract Manufacturing Organisations (CMOs)
    • 5.2.1. Manufacturing Services Offered by CMOs
    • 5.2.2. Vaccine Manufacturing Activities Typically Outsourced
  • 5.3. The Vaccine Contract Manufacturing Market: Overall Revenue Forecast 2019-2029
  • 5.4. Contract Manufacturing Market for Vaccines 2018-2029
    • 5.4.1. Market Size for Contract Manufacturing of Vaccines 2018
    • 5.4.2. Vaccine Contract Manufacturing Market Forecast 2019-2029

6. Vaccine Contract Manufacturing Market by Vaccine Type, 2019-2029

  • 6.1. Paediatric Vaccines
  • 6.2. Adult Vaccines
  • 6.3. Influenza Vaccines
  • 6.4. Therapeutic Vaccines

7. Vaccine Contract Manufacturing Market by Workflow, 2019-2029

  • 7.1. Downstream Processing
    • 7.1.1. Fill & Finish Operations
    • 7.1.2. Analytical & QC Studies
    • 7.1.3. Packaging
  • 7.2. Upstream Processing
    • 7.2.1. Mammalian Expression Systems
    • 7.2.2. Bacterial Expression Systems
    • 7.2.3. Yeast Expression Systems
    • 7.2.4. Baculovirus/Insect Expression Systems
    • 7.2.5. Other Upstream Processing

8. Leading National Markets for Vaccine Contract Manufacturing, 2019-2029

  • 8.1. Leading National Markets for Vaccine Contract Manufacturing
  • 8.2. North America Vaccine Contract Manufacturing Market, 2018-2029
    • 8.2.1. US Vaccine Contract Manufacturing Market Forecast, 2018-2029
    • 8.2.2. Canada Vaccine Contract Manufacturing Market Forecast, 2018-2029
  • 8.3. The Europe Vaccine Contract Manufacturing Market, 2018-2029
    • 8.3.1. Germany Vaccine Contract Manufacturing Market, 2016-2028
    • 8.3.2. UK Vaccine Contract Manufacturing Market, 2018-2029
    • 8.3.3. French Vaccine Contract Manufacturing Market, 2018-2029
    • 8.3.4. Italy Vaccine Contract Manufacturing Market, 2018-2029
    • 8.3.5. Spain Vaccine Contract Manufacturing Market, 2018-2029
  • 8.4. Asia-Pacific Vaccine Contract Manufacturing Market, 2018-2029
    • 8.4.1. Japan Vaccine Contract Manufacturing Market, 2018-2029
    • 8.4.2. China Vaccine Contract Manufacturing Market, 2018-2029
    • 8.4.3. India Vaccine Contract Manufacturing Market, 2018-2029
  • 8.5. Rest of the World Vaccine Contract Manufacturing Market, 2018-2029
    • 8.5.1. Brazil Vaccine Contract Manufacturing Market, 2018-2029
    • 8.5.2. Mexico Vaccine Contract Manufacturing Market, 2018-2029
    • 8.5.3. Russia Vaccine Contract Manufacturing Market, 2018-2029
    • 8.5.4. South Africa Vaccine Contract Manufacturing Market, 2019-2029

9. Leading Vaccine Contract Manufacturing Companies, 2018-2029

  • 9.1. Leading Vaccine Contract Manufacturing Organisations
  • 9.2. Baxter BioPharma Solutions
    • 9.2.1. Recent Financial Performance
    • 9.2.2. Key Developments
  • 9.3. Boehringer Ingelheim
    • 9.3.1. Recent Financial Performance
    • 9.3.2. Ben Venue Laboratories
    • 9.3.3. Manufacturing Deals 2011-2017
  • 9.4. Catalent
    • 9.4.1. Recent Financial Performance
    • 9.4.2. Catalent: Financial Performance by Segment, 2011-2016
    • 9.4.3. Catalent Injectable Vaccines
    • 9.4.4. Catalent: Zydis Technology
    • 9.4.5. Regional Market Expansion Strategy
  • 9.5. Charles River Laboratories
    • 9.5.1. Recent Financial Performance, 2011-2017
    • 9.5.2. Financial Performance by Segment, 2012-2018
    • 9.5.3. Vaccine Manufacturing Services
    • 9.5.4. Charles River Avian Vaccine Services
    • 9.5.5. Vaccine Manufacturing Expansion
    • 9.5.6. Outlook and Early Stage Restructuring
    • 9.5.7. Partnerships
      • 9.5.7.1. Partnership with AstraZeneca
      • 9.5.7.2. Partnership with Batavia
  • 9.6. IDT Biologika GmbH
  • 9.7. Lonza
    • 9.7.1. Recent Financial Performance
    • 9.7.2. Manufacturing Division Restructuring
  • 9.8. Meridian Life Science
    • 9.8.1. Recent Financial Performance, 2012-2018
  • 9.9. Sigma-Aldrich Fine Chemicals (SAFC) (Merck KGaA)
  • 9.10. SynCo Bio Partners
    • 9.10.1. Recent Developments
      • 9.10.1.1. Expansion of Facilities
      • 9.10.1.2. FDA Approval of Partner Application
  • 9.11. AbbVie Contract Manufacturing
    • 9.11.1. AbbVie Offers Full-Service Contract Manufacturing
    • 9.11.2. Recent Financial Performance: Revenue 2012-2017
    • 9.11.3. Strategic Developments 2017-2018
  • 9.12. Evonik Degussa
    • 9.12.1. API and Drug Delivery Services
  • 9.13. Vetter Pharmaceutical
    • 9.13.1. Financial Performance, 2013-2017
    • 9.13.2. Regional Expansion
  • 9.14. Pfizer CentreOne
    • 9.14.1. Financial Performance, 2013-2018
    • 9.14.2. Strategic Developments 2017-2018
  • 9.15. Nipro Corporation
    • 9.15.1. Contract Manufacturing Capabilities

10. Global Vaccine Contract Manufacturing Market: World Market Trends 2018-2029

  • 10.1. Vaccine Contract Manufacturing Industry Trends
  • 10.2. Strengths
    • 10.2.1. Many Companies Cannot Afford In-house Capabilities
    • 10.2.2. Outsourcing Improves Time to Market
    • 10.2.3. Manufacturers Get Access to Specialised Technologies
    • 10.2.4. Shift Towards Emerging Markets as Favourable Outsourcing Destinations
  • 10.3. Weaknesses
    • 10.3.1. Mass Vaccine Manufacturing Kept In-house
    • 10.3.2. A Highly-Fragmented Vaccine Contract Manufacturing Market
    • 10.3.3. An Unpredictable Supply and Demand Business Model
  • 10.4. Opportunities
    • 10.4.1. Many Vaccines in the Product Pipeline
    • 10.4.2. Emerging Market's Growing Demand for Vaccines
      • 10.4.2.1. Dynamic Change: Emerging Markets are Major Vaccine Developers
    • 10.4.3. Changing World Demographics
  • 10.5. Threats
    • 10.5.1. Post Recession: Biotech Suffer from Severe Cuts in Capital Funding
    • 10.5.2. The Public are Slow to Accept Novel Technologies
    • 10.5.3. Perception of Risk by the Original Vaccine Manufacturers

11. Conclusion

  • 11.1. Overview
  • 11.2. Regulatory and Quality Standards Create High Barriers of Entry
  • 11.3. Emerging Markets Will Show Stronger Growth

Appendices

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain report evaluation form
Back to Top
전화 문의
F A Q